{"id":849082,"date":"2025-05-08T08:48:06","date_gmt":"2025-05-08T12:48:06","guid":{"rendered":""},"modified":"2025-05-08T08:48:06","modified_gmt":"2025-05-08T12:48:06","slug":"gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/","title":{"rendered":"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0"},"content":{"rendered":"
\n

\n The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed<\/em>\n <\/p>\n

\n Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial<\/em>\n <\/p>\n

\n Results on track for interim data in Q2 2025 and topline data in Q3 2025<\/em>\n <\/p>\n

\n Management releases \u201cWhat This Means\u201d segment discussing the interim biomarker data; <\/em>
\n
\n Access Here<\/em>
\n <\/a>\n <\/p>\n

\n LA JOLLA, CA, May 08, 2025 (GLOBE NEWSWIRE) — <\/strong>
\n GRI Bio, Inc.<\/a> (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported interim biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d). Additionally, management participated in a Virtual Investor \u201cWhat This Means\u201d segment to discuss the interim biomarker data. The segment is now available here<\/a>.<\/p>\n

The IDMC has examined the change from baseline biomarkers from the first 12 subjects at 2 weeks and determined the change from baseline in PRO-C3 of GRI-0621-treated patients compared to placebo patients is suggestive of anti-fibrotic effect. Based on the available interim data reviewed, the IDMC has recommended the Phase 2a study evaluating GRI-0621 to continue as planned as there are no safety concerns seen to date.<\/p>\n

\u201cWhile still early and in a small number of subjects, the trend in anti-fibrotic effect seen with GRI-0621 is very encouraging. We believe that these data, in combination with the early safety data and consistent toxicity profile with tazarotene, underscores GRI-0621\u2019s potential to provide a safe and effective treatment option that inhibits NKT cell activity in this patient population, providing much needed benefit to patients,\u201d commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. \u201cWe have also completed enrollment for the 6-week interim data, and with almost 70% of the total study subjects enrolled, we remain on track to report topline data in the third quarter of 2025.\u201d<\/p>\n

The Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study will enroll approximately 36 subjects with IPF whom will be randomized in a 2:1 ratio for GRI-0621 4.5mg or a placebo. GRI-0621 dose of 4.5mg will be compared with a dose of placebo following once daily oral administration for 12 weeks. Concurrently, a sub-study will examine the number and activity of NKT cells in bronchoalveolar lavage (\u201cBAL\u201d) fluid for up to 12 eligible subjects (across various centers). An interim analysis will be performed when 24 subjects (of which approximately 8 will be placebo subjects) complete 6 weeks of treatment. The primary endpoint for the study is safety and tolerability of oral GRI-0621 as assessed by clinical labs, vital signs and adverse events after 12 weeks of treatment. Secondary endpoints are baseline changes in serum biomarkers collected at week 6 and week 12; an assessment of the pharmacokinetics (PK) of GRI-0621 at the week 12 visit of treatment (steady state); and a determination of the pharmacodynamic activity of oral GRI-0621 as measured by inhibition of iNKT cell activation in blood after 6 weeks and 12 weeks, and from BAL fluid after 12 weeks of treatment in a sub-study. Additional exploratory endpoints for the study are to assess the effect of GRI-0621 on pulmonary function at baseline and after 6 weeks and 12 weeks of treatment and flow cytometry and differential gene expression at various time points.<\/p>\n

As previously announced, the pre-planned interim analysis for 2-week safety results from the ongoing Phase 2a biomarker study demonstrated GRI-0621 (4.5mg orally once daily) to be safe and well-tolerated in the first 12 patients evaluated per protocol. Hyperlipidemia, as assessed by LDL, HDL and triglyceride (TG) levels, was not seen in the 12 patients assessed at the 2-week visit. There were no meaningful changes in HDL, LDL or TG levels in patients receiving GRI-0621, and all subjects remained within normal ranges. The interim analysis committee recommended the study should continue as planned. The interim results show that GRI-0621\u2019s receptor selectivity is consistent with the toxicity profile observed in earlier studies evaluating oral tazarotene in over 1,700 patients treated for up to 52 weeks.<\/p>\n

Topline results from the Phase 2a biomarker study are expected in the third quarter of 2025.<\/p>\n

For more information about the Phase 2a study, please visit clinicaltrials.gov<\/a> and reference identifier NCT06331624.<\/p>\n

\n About GRI Bio, Inc.<\/strong>\n <\/p>\n

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio\u2019s therapies are designed to target the activity of Natural Killer T (\u201cNKT\u201d) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (\u201ciNKT\u201d) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio\u2019s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (\u201cdNKT\u201d) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions. These forward-looking statements are based on the Company\u2019s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company\u2019s expectations with respect to development and commercialization of the Company\u2019s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company\u2019s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company\u2019s beliefs and expectations regarding potential shareholder value and future financial performance, the Company\u2019s beliefs and estimates about its cash and available resources and its ability to fund its planned operations through any particular date, the Company\u2019s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company\u2019s expected milestones in 2025, and the Company\u2019s beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its planned operations, its ability to raise additional funds, which may not be available to the Company on acceptable terms, or at all, and capital expenditure requirements. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company\u2019s common stock on The Nasdaq Capital Market and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company\u2019s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company\u2019s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company\u2019s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company\u2019s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company\u2019s filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), including the risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC on March 14, 2025 and subsequently filed reports. In particular, the data discussed in this release is interim data and additional study and additional favorable results will be needed for development of GRI-0621 to continue; this interim data may not be indicative of later or final data for this trial. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.<\/p>\n

Investor Contact:<\/strong>
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for interim data in Q2 2025 and topline data in Q3 2025 Management releases \u201cWhat This Means\u201d segment discussing the interim biomarker data; Access Here LA JOLLA, CA, May 08, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported interim biomarker … <\/p>\n

Continue reading “GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0“<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-849082","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for interim data in Q2 2025 and topline data in Q3 2025 Management releases \u201cWhat This Means\u201d segment discussing the interim biomarker data; Access Here LA JOLLA, CA, May 08, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported interim biomarker … Continue reading "GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T12:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0\",\"datePublished\":\"2025-05-08T12:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/\"},\"wordCount\":1572,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/\",\"name\":\"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==\",\"datePublished\":\"2025-05-08T12:48:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/","og_locale":"en_US","og_type":"article","og_title":"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0 - Market Newsdesk","og_description":"The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for interim data in Q2 2025 and topline data in Q3 2025 Management releases \u201cWhat This Means\u201d segment discussing the interim biomarker data; Access Here LA JOLLA, CA, May 08, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported interim biomarker … Continue reading \"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-08T12:48:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0","datePublished":"2025-05-08T12:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/"},"wordCount":1572,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/","name":"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==","datePublished":"2025-05-08T12:48:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkwMSM2OTI4NDM2IzUwMDA3NTQ4OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bios-interim-biomarker-data-demonstrate-positive-trend-towards-anti-fibrotic-effect-of-gri-0621-in-first-twelve-patients-of-ongoing-phase-2a-study-in-idiopathic-pulmonary-fibrosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GRI Bio\u2019s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=849082"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849082\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=849082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=849082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=849082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}